Efavirenz 600mg / Emtricitabine 200mg / Tenofovir disoproxil 245mg tablets
NHS hospitals in England used £19,545,085 of indicative cost of Efavirenz 600mg / Emtricitabine 200mg / Tenofovir disoproxil 245mg tablets in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is down 11.1% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Efavirenz 600mg / Emtricitabine 200mg / Tenofovir disoproxil 245mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Efavirenz 600mg / Emtricitabine 200mg / Tenofovir disoproxil 245mg tablets most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Manchester University Nhs Ft | £987,124 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £923,464 |
| King's College Hpl Nhs Foundation Trust | £915,471 |
| Imperial College Healthcare Nhs Trust | £857,388 |
| Univ Hpl B/Ham Nhs Foundation Trust | £839,803 |
| Western Sussex Hospitals Nhs Found Trust | £691,132 |
| London North West Healthcare Nhs Trust | £690,031 |
| University College London Foundation Tr | £687,775 |
| Ctrl & N W London Nhs Foundation Trust | £677,811 |
| Lewisham And Greenwich Nhs Trust | £661,825 |
The primary-care picture
Efavirenz is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Efavirenz medicine page.